Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03955783
Recruitment Status : Recruiting
First Posted : May 20, 2019
Last Update Posted : July 1, 2019
Sponsor:
Collaborators:
Karyopharm Therapeutics Inc
AbbVie
Information provided by (Responsible Party):
Michael Byrne, Vanderbilt-Ingram Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2022